Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it
Page 10 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA MutationCompletedNCT01472783Phase 1/2
- Radiotherapy & Olaparib in COmbination for Carcinoma of the OesophagusStatus unknownNCT01460888Phase 1
- Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT01459380Phase 1
- ABT-888 Plus Metronomic Cyclophosphamide to Treat CancerCompletedNCT01445522Phase 1
- AZD2281 Plus Carboplatin to Treat Breast and Ovarian CancerCompletedNCT01445418Phase 1
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT01434316Phase 1
- ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney ProblemsWithdrawnNCT01419548Phase 1
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1
- Olaparib and Temozolomide in Treating Patients With Relapsed GlioblastomaCompletedNCT01390571Phase 1
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01351909Phase 1
- Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell LymphomaCompletedNCT01345357Phase 1
- Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01339650Phase 1
- Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedNCT01294735Phase 1
- Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
- Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical CancerCompletedNCT01281852Phase 1
- Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT01281150Phase 1
- Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerCompletedNCT01264432Phase 1
- Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingNCT01251874Phase 1
- An Open-Label, Dose-Escalation Study of AZD2461CompletedNCT01247168Phase 1
- A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)WithdrawnNCT01244009Phase 2
- Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersCompletedNCT01237067Phase 1
- Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
- MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)TerminatedNCT01227941Phase 1
- A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)TerminatedNCT01226901Phase 1
- Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid TumorsCompletedNCT01213381Phase 1
- Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer PatientsCompletedNCT01204125Phase 2
- To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid TumorsCompletedNCT01199224Phase 1
- To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid TumorsCompletedNCT01193140Phase 2
- A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain MetastasisCompletedNCT01173497Phase 2
- An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)CompletedNCT01161836Phase 1
- ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01154426Phase 1
- Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerCompletedNCT01145430Phase 1
- Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
- Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid TumorCompletedNCT01123876Phase 1
- A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian CancerCompletedNCT01113957Phase 2
- Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerCompletedNCT01104259Phase 1
- SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung CancerCompletedNCT01086254Phase 2
- A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate CancerCompletedNCT01085422Phase 1
- Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01082549Phase 3
- A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsCompletedNCT01063816Phase 1
- Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast CancerCompletedNCT01045304Phase 2
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT01033292Phase 2
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian CancerCompletedNCT01033123Phase 2
- A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic RegimensCompletedNCT01009190Phase 1
- A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS TumorsCompletedNCT00994071Phase 1
- ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
- A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast CancerCompletedNCT00938652Phase 3
- Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid TumorsCompletedNCT00920595Phase 1
- Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyCompletedNCT00892736Phase 1
- AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid TumoursTerminatedNCT00819221Phase 1
- A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast CancerCompletedNCT00813956Phase 2
- Phase I AZD2281/Cisplatin in Advanced Solid Tumour PatientsCompletedNCT00782574Phase 1
- Phase I Comparative Bioavailability StudyActive, not recruitingNCT00777582Phase 1
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin LymphomaActive, not recruitingNCT00740805Phase 1
- Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid TumoursCompletedNCT00710268Phase 1
- Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerCompletedNCT00707707Phase 1
- Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant GliomaCompletedNCT00687765Phase 1/2
- Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine CarcinosarcomaCompletedNCT00687687Phase 2
- AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor CancersCompletedNCT00678132Phase 1
- Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00677079Phase 2
- Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian CancerCompletedNCT00664781Phase 2
- A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain MetastasesCompletedNCT00649207Phase 1
- Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic TumoursCompletedNCT00633269Phase 1
- Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersCompletedNCT00588991Phase 1
- Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT00576654Phase 1
- Open Label, Dose Escalation Phase I Study of AZD2281CompletedNCT00572364Phase 1
- Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and LymphomasCompletedNCT00553189Phase 1
- A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast CancerCompletedNCT00540358Phase 2
- Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid CancerCompletedNCT00535119Phase 1
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsCompletedNCT00526617Phase 1
- A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With DacarbazineCompletedNCT00516802Phase 1
- Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With TopotecanCompletedNCT00516438Phase 1
- A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)CompletedNCT00516373Phase 1
- Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic CancerCompletedNCT00515866Phase 1
- A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)WithdrawnNCT00457470Phase 2
- A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid TumorsCompletedNCT00422682Phase 1
- Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer PatientsStatus unknownNCT00411853Phase 2
- ABT-888 in Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00387608Phase 1
- A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With MelanomaTerminatedNCT00272415Phase 1
- A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary InterventionCompletedNCT00271765Phase 2
- A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung BypassTerminatedNCT00271167Phase 2